Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...
Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...
Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...
Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...
Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...
Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...
Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...
Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...
Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment ...
Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update ...